First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors
首次在人体中研究钍-227标记的间皮素靶向抗体螯合剂偶联物(MSLN-TTC)在恶性间皮瘤和其他实体瘤患者中的疗效
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105905
Minchom, A; Lindén, O; Knapen, D G; Hassan, R; Lin, F I; Jalkanen, K; Subbiah, V; Tafuri, A; Ferreira, D; Jardine, V; Cleton, A; Pinkert, J; Bladt, F; Hennekes, H; Smit, E F